This page is available in multiple languages
EnterNext welcomes Abivax on Euronext in Paris
Professor Hartmut Ehrlich, CEO of Abivax, rings the closing bell.
Abivax specializes in the research, development and commercialization of anti-viral drugs and therapeutic vaccines for the treatment of severe infectious diseases.
At the end of 2014, the Group has a portfolio of three products in clinical development: ABX203 (therapeutic vaccine against chronic hepatitis B), ABX464 (new drug against HIV) and ABX196 (adjuvant vaccine against hepatitis B).